Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Louis Lange Insider Profile
4 Followers
Louis Lange, Director at CymaBay Therapeutics, holds 24.88K shares in NewAmsterdam Pharma Company (Ticker: NAMS), holds 0.00 shares in Audentes Therapeutics (Ticker: ~BOLD), holds 1.45K shares in CymaBay Therapeutics (Ticker: CBAY). Most recently, Louis Lange Bought ― shares of NewAmsterdam Pharma Company on Feb 21, 2024 for an estimated value of 95.00K.
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-14.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Louis Lange holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Feb 21, 2024 - Today
Return:-6.80%
The most profitable trade made by Louis Lange
Louis Lange's Trading History
CymaBay Therapeutics
Oct 11, 2013
―
Uninformative Buy
―
$46.97K
Audentes Therapeutics
Jan 15, 2020
―
Uninformative Sell
18.92M
$0.00
NewAmsterdam Pharma Company
Feb 21, 2024
Director
Informative Buy
95.00K
$487.11K
Esperion
Jul 01, 2013
Director
Uninformative Buy
―
$512.93K
Gilead Sciences
―
Former EVP Cardio Therapeutics
―
$0.00
Maxygen
―
―
―
―
List of latest transactions for each holding click on a transaction to see Louis Lange's performance on stock
You May Also Like
Louis Lange insider profile FAQ
What is the percentage of profitable transactions made by Louis Lange?
The percentage of profitable transactions made by Louis Lange is 0%.
What is the average return per transaction made by Louis Lange?
The average return per transaction made by Louis Lange is -14.80%.
What stocks does Louis Lange hold?
Louis Lange holds: CBAY, ~BOLD, NAMS, ESPR, GILD, MAXY stocks.
What was Louis Lange’s latest transaction?
Louis Lange latest transaction was an Informative Buy of $95.00K.
What was Louis Lange's most profitable transaction?
Louis Lange’s most profitable transaction was an Informative Buy of NAMS stock on February 21, 2024. The return on the trade was -6.80%.
What is Louis Lange's role in CymaBay Therapeutics?
Louis Lange's role in CymaBay Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.